Stock Events

Stock Events

OKYO Pharma Limited 

€1.4100
23
+€0.00+0% Tuesday 20:00

Statistics

Day High
1.41
Day Low
1.41
52W High
2.7
52W Low
0.855
Volume
0
Avg. Volume
0
Mkt Cap
74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q4 2025
Q2 2026
Next
-0.13
-0.09
-0.05
-0.01
Expected EPS
-0.051612
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.7MNet Income

Analyst Ratings

3.79Average Price Target
The highest estimate is 3.79.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OK10.STU. It's not an investment recommendation.
Realty Income
3
O
Bitcoin
3
BTC.CRYPTO
NVIDIA
2
NVDA
AMD
2
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. competes in the biopharmaceutical sector focusing on ophthalmology among other areas, directly competing with OKYO's eye disease treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its ophthalmology division, competes in developing treatments for eye diseases, similar to OKYO Pharma's focus.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a strong presence in the pharmaceuticals market, including treatments for eye conditions that compete with OKYO's product pipeline.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies Inc., through its eye health products, competes directly with OKYO Pharma in the ophthalmology market.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, positioning it as a competitor to OKYO Pharma's eye disease treatments.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. has investments in therapies for neurological conditions, some of which include ophthalmologic applications, indirectly competing with OKYO.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is broadly in the biopharmaceutical field with a focus on viral diseases but its expansion into other areas can position it as a competitor to OKYO.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diverse pharmaceutical portfolio, including investments in treatments for eye diseases, making it a potential competitor to OKYO Pharma.

About

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Show more...
CEO
Robert J. Dempsey
Employees
5
Country
United Kingdom
ISIN
US6793451088
WKN
000A3DLA6

Listings

MU
DE
OK10.MU
STU
DE
OK1.STU
MU
DE
OK11.MU
STU
DE
OK10.STU

0 Comments

Share your thoughts

FAQ

What is OKYO Pharma Limited stock price today?▼
The current price of OK10.STU is €1.41 EUR — it has increased by +0% in the past 24 hours. Watch OKYO Pharma Limited stock price performance more closely on the chart.
What is OKYO Pharma Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange OKYO Pharma Limited stocks are traded under the ticker OK10.STU.
What is OKYO Pharma Limited market cap?▼
Today OKYO Pharma Limited has the market capitalization of 74M
When is the next OKYO Pharma Limited earnings date?▼
OKYO Pharma Limited is going to release the next earnings report on December 02, 2026.
What were OKYO Pharma Limited earnings last quarter?▼
OK10.STU earnings for the last quarter are -0.13 EUR per share, whereas the estimation was -0.07 EUR resulting in a -87.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is OKYO Pharma Limited revenue for the last year?▼
OKYO Pharma Limited revenue for the last year amounts to 0 EUR.
What is OKYO Pharma Limited net income for the last year?▼
OK10.STU net income for the last year is -7.7M EUR.
How many employees does OKYO Pharma Limited have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is OKYO Pharma Limited located?▼
OKYO Pharma Limited operates in the Health & Wellness sector.
When did OKYO Pharma Limited complete a stock split?▼
OKYO Pharma Limited has not had any recent stock splits.
Where is OKYO Pharma Limited headquartered?▼
OKYO Pharma Limited is headquartered in London, United Kingdom.